Skip to main content
NewslettersWatchlist

Abbvie Inc(ABBV-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low166.92
Day High172.46
Open:168.59
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Where Will AbbVie Be in 5 Years?
Motley Fool
Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip
Barchart
3 Oversold Dividend Aristocrats Ready To Explode in 2025
Motley Fool
Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock
Motley Fool
2 Dividend Stocks to Buy Hand Over Fist in November
Barchart
What's Behind the Insider Buying on This High-Yield Stock?
Barchart
Stocks Settle Mostly Higher on President-Elect Trump’s Pro-Growth Promises
Motley Fool
Why AbbVie Stock Was Getting Mashed on Monday
Barchart
Is This Dividend King a Buy After a Strong Q3 Report?
Barchart
Stocks Rally on Optimism in President-Elect Trump’s Policies
Barchart
S&P 500 and Dow Jones Industrials at Record Highs as the Post-Election Rally Continues
Motley Fool
3 Spectacular High-Yield Dividend Stocks to Buy in November
Motley Fool
My Favorite Dividend King to Buy in November
Motley Fool
2 Dividend Kings That Would Have Doubled Your Money in 5 Years
MarketBeat
Is Eli Lilly a Buy? Analyst Confidence Grows for 2025
MarketBeat
Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings
Baystreet
Invest in the Top S&P Stocks With This New ETF
MarketBeat
High-Yield AbbVie Gains Momentum: A 20% Upside Is in Sight
Motley Fool
5 Dividend Stocks to Double Up on Right Now -- Plus Some Dividend ETFs
Motley Fool
AbbVie (ABBV) Q3 2024 Earnings Call Transcript
Motley Fool
3 Dividend Growth Stocks to Buy and Never Sell
Barchart
Nasdaq Futures Climb on Upbeat Alphabet Results, U.S. GDP Data and More Big Tech Earnings on Tap

Profile

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.